Company Deck
June 2024
Forward Looking Statements
This Presentation may include statements, including the Company's financial and operational medium-
term objectives, that may be deemed to be ''forward-looking statements''. These forward-looking statements may be identified by the use of forward-looking terminology, including the terms '' believes''," aims"," forecasts"," continues",'' estimates'','' plans'','' projects'','' anticipates'','' expects'','' intends'','' may'','' or '' or, in each case, their negative or other variations or comparable terminology, or by discussions of strategy, plans, objectives, goals, future events or intentions. Forward-looking statements may and often do differ materially from actual results. Any forward-looking statements reflect the Company's current
view concerning future events and are subject to risks relating to future events and other risks, uncertainties, and assumptions relating to the Company's business, results of operations, financial
position, liquidity, prospects, growth, or strategies. Forward-looking statements speak only as of the date they are made.
ONWARD Medical Company Deck | 2 |
Company Overview
Key Facts
- Founded in 2015
- ~100 FTEs
- HQ in the Netherlands
- Science and Engineering Center in Switzerland
- Growing US presence
- IPO 2021, Euronext Brussels and Amsterdam
- Followed by Stifel, Bryan, Garnier & Co, KBC Securities, Degroof Petercam and Kepler Cheuvreux
ONWARD® Medical at a Glance
Technology: 3 purpose-built neuromodulation platforms
-
ARCEX® delivers ARC Therapy externally through the skin o ARCIM® delivers ARC Therapy via a fully implanted system
o ARCBCI pairs ARCIM with an implanted brain-computer interface to restore thought- driven movement via a wireless DigitalBridge
Innovation: 10 FDA Breakthrough Device Designations; 265+ issued patents1
Clinical Success:
- Safety and effectiveness of ARCEX Therapy for upper limb mobility demonstrated in Up-LIFT clinical trial; results published in Nature Medicine, May 2024
- Positive interim results for ARCIM Therapy to improve blood pressure regulation
Market Opportunity: $20B+ / €19B+ total addressable market with limited competition
Commercialization: First revenues expected 2H 2024 with ARCEX launch
Note: 1 EUR = 1.1 USD; FTE figures as of end of Q4 2023; patent figures as of end of Q1 2024
1 Includes EP country validations
ONWARD Medical Company Deck | 4 |
There are no cures nor effective therapies
for spinal cord injury (SCI)
Devastating | Prevalent |
Not only paralysis & loss of | US & Europe1,2 |
sensation; frequently also | Prevalence ~650,000 |
infection, incontinence, blood | Incidence ~50,000 |
pressure instability, loss of sexual | |
function, and other challenges | Global2 |
Prevalence ~7,000,000 | |
Assistance required to support | Incidence ~768,000 |
activities of daily life | |
Quality of life can be poor |
Unmet Need
Costly
Avg Lifetime Cost3 (paraplegic)
$2.9M/€2.6M
Avg Lifetime Cost3 (tetraplegic)
$5.1M/€4.6M
Note: 1 EUR = 1.1 USD
- NSCISC Annual Report, US and Europe only, World Health Organization Fact Sheet, November 2013, estimate 40-80 cases per million
- Kumar et al. 2018, Traumatic Spinal Injury: Global Epidemiology and Worldwide Volume
- NSCISC Traumatic Spinal Cord Injury Facts and Figures at a Glance (2023 SCI Data Sheet); estimated lifetime costs for a person aged 25 at the time of injury with injury severity AIS ABC; costs for a tetraplegic person calculated as the average cost for a person with high tetraplegiaand a person with low tetraplegia
ONWARD Medical Company Deck | 5 |
Targeted, programmed electrical stimulation of the | Our Technology |
spinal cord to restore movement, function, and independence in people with spinal cord injury
Note: Investigational devices, not available for commercial use. The ARCBCI graphical representation includes ONWARD Medical's ARCIM with CEA Clinatec's WIMAGINE® brain-computer interface.
ONWARD Medical Company Deck | 6 |
Reach commercial stage by year-end,
then expand labeling and platforms
Company Focus
Short Term | Medium Term | Long Term |
2024 | 2026 | 2026+ |
Commercialize external platform (ARCEX) | Commercialize implantable platform (ARCIM) |
First indication: Upper Limb | First indication: Blood Pressure |
Population: SCI | Population: SCI |
Generate revenue and develop market for ARCIM | Enter traditional medtech IPO/M&A window |
Expand labeling and platforms
New indications and platforms to be assessed such as BCI
Populations: SCI, Parkinson's, Stroke
Note: Investigational devices, not available for commercial use; SCI = Spinal Cord Injury. The ARCBCI graphical representation includes ONWARD Medical's ARCIM with CEA Clinatec's WIMAGINE® brain-computer interface.
ONWARD Medical Company Deck | 7 |
9 indications under clinical or pre-clinical evaluation, with 3 in current roadmap
Short and medium term focus | Funded primarily through grants and research partners |
Current Pipeline
Platform | Indication | FDA BDD1 Pre-clinical | Human PoC | Clinical | Pivotal |
Feasibility2 | |||||
ARCEX | Upper Limb | ||||
ARCIM | Blood Pressure | ||||
ARCIM | Mobility / Second | ||||
Indication | |||||
ARCEX | Mobility | ||||
ARCIM | Parkinson's - Mobility | ||||
ARCIM | Bladder | Human PoC | |||
expected in 20243 | |||||
ARCBCI | Mobility | ||||
ARCBCI | Upper Limb | ||||
ARCDBS | Mobility | ||||
BDD1 Granted | Current Roadmap | Label Expansion | Platform Expansion |
Note: The company may modify the pipeline based on clinical progress and marketplace considerations
- BDD = FDA Breakthrough Device Designation. ONWARD has been granted four additional BDDs for ARCEX Bladder, ARCEX Blood Pressure, ARCEX Spasticity and ARCIM Spasticity
- Includes both early feasibility (typically before device design finalized) and feasibility (near-final or final device design) studies
- Funded by Christopher & Dana Reeve Foundation grant
ONWARD Medical Company Deck | 8 |
Technology and Evidence
External system for non-invasive,
programmed stimulation of the spinal cord
ARCEX® Therapy
Programmed transcutaneous electrical stimulation to the spinal cord
Designed to restore movement, function, and independence in people with SCI
ARCEX® Stimulator
Note: For investigational use only
External Platform
ARCEX® PRO & myARCEX® app
via ARCEX® Programmer
ARCEX® Therapy
Individual stimulation parameters can be optimized for each patient's unique needs
ONWARD Medical Company Deck | 10 |
Attachments
- Original Link
- Original Document
- Permalink
Disclaimer
ONWARD Medical NV published this content on 12 June 2024 and is solely responsible for the information contained therein. Distributed by Public, unedited and unaltered, on 12 June 2024 15:20:04 UTC.